The integration of immune checkpoint inhibitors, particularly PD-L1 inhibitors, into the treatment regimen for extensive-stage small-cell lung cancer (SCLC) has significantly altered the clinical landscape. The gene discussed is CD274; the disease is small cell lung carcinoma.